## Summary

This paper evaluates small language models (≤3B) and small vision-language models against larger medically-adapted counterparts on clinical text summarization (MeQSum) and radiology report generation (MIMIC-CXR). It applies in-context learning and PEFT methods (LoRA, QLoRA) and introduces a "Collapse Analysis" framework to measure task adherence, hallucination rates, concept recall, and prompt robustness. The paper identifies a "safety collapse" threshold around 1B parameters and finds that while fine-tuned small LMs appear competitive with large LMs in text summarization, small VLMs consistently lag behind large VLMs in radiology reporting.

## Strengths

- **The "safety collapse" finding (Table 3) identifies sharp degradation in hallucination rates below ~1B parameters (2-3% at ≥1.7B spiking to 18-75% below 360M).** This finding, if validated with transparent methodology, could guide deployment decisions about minimum viable scale.

- **The VLM experiments (Section 3.3, Table 4) are better controlled:** small VLMs (Florence 2 0.77B, Qwen 2.5-VL 3B) are fine-tuned on 10K image-report pairs and compared against large medical VLMs. The clear negative result — small VLMs consistently lag behind larger counterparts — provides useful, credible guidance about where scale remains necessary.

## Weaknesses

### Fatal
None.

### Major

- **The central LM comparison is structurally confounded.** Small LMs are fine-tuned via LoRA (Section 3.2, line 120: "we applied...PEFT methods...to each small LLM") while the large LMs — BioMistral-7B, Med-LLaMA-8B, OpenBioLLM-8B — are evaluated only in zero-shot/ICL; their LoRA columns in Figure 3 are marked with dashes. The paper then claims "After LoRA fine-tuning, all small LMs outperformed large LMs across every metric" (line 231) and "model scale can be traded for adapter efficiency without sacrificing quality" (line 247). This compares fine-tuned 1B models against zero-shot 7-8B models. A properly controlled experiment would fine-tune both small and large models under identical conditions. Without that, the paper's headline claim is uninterpretable.

- **The "Collapse Analysis" framework — presented as a core contribution (lines 23-26) — has no methodology defined for any of its dimensions.** Task Adherence, Hallucination Rate, Clinical Concept Recall, Prompt Robustness, and the composite Readiness Score (Table 3) are named and reported with numerical values, but the paper never specifies how any of these are computed (automated scoring vs. human annotation, rubrics, thresholds, annotator agreement). Lacking this, the central finding of a "safety collapse" at ~1B cannot be evaluated, reproduced, or trusted.

### Minor

- **Model identity problems.** (a) "SmolLM3-3B" (Table 3, line 126) does not exist in the SmolLM2 family. (b) "MeQ-Small corpus" (line 231) appears once without definition (the dataset is MeQSum). (c) Naming is inconsistent (SmollM2 vs SmolLM2, Llama-3.2-16 vs LLaMA-3.2 (1B)). These issues make it difficult to determine which models were actually evaluated.

- **Table 4 does not specify the evaluation condition for large VLMs** (Med-Flamingo 9B, LLaVA-Med 7B). The text says small VLMs were fine-tuned and then "compare[d]...against two large medical VLMs" (line 219), but whether the large VLMs were also fine-tuned, used zero-shot, or evaluated in their pretrained form is unclear.

- **BERTScore discrepancy.** Llama-3.2 (1B) zero-shot BERTScore is reported as 0.7632 in Table 2, but the ICL column of Figure 3 shows ~52% (0.52) for "Llama-3.2-16." This 24-point gap needs explanation (possibly different prompt configurations or shot-counts).

- **Fine-tuning hyperparameters are absent.** LoRA rank, learning rate, batch size, number of epochs, quantization settings for QLoRA, and the train/validation split are not reported (Section 3.2). This hinders reproducibility.

- **Broken cross-reference.** Line 219 reads "From Table ??" — the table number is missing.

### Trivial
None.

## Nice-to-Haves
- Fine-tune large LMs under identical conditions to validate the scale-efficiency claim.
- Provide explicit operational definitions for each collapse-analysis dimension.
- Add error bars or confidence intervals for the 250-sample test set.

## Removed Points
- *Criticism about missing error bars / confidence intervals / statistical tests*: Not standard for all benchmarking papers of this type; not a core flaw.
- *Criticism about Figure 2 comparing fine-tuned vs non-fine-tuned models*: Already captured under the first Major weakness.
- *Strength about "addressing an important question"*: Generic, lacks specific evidence anchor.
- *Criticism about missing appendix / proofs*: Parser strips these; they exist in the original submission.

## Novel Insights
None beyond the paper's own contributions. The reviews primarily identify design flaws rather than surfacing new interpretations of the data.

## Suggestions
1. Fine-tune the large LMs (BioMistral-7B, Med-LLaMA-8B, OpenBioLLM-8B) under identical LoRA conditions and re-run the comparison. This is the single most important fix.
2. Fully specify how each collapse-analysis dimension is computed (automated metrics, human rubrics, thresholds, annotator agreement).
3. Resolve model identity issues: correct SmolLM3-3B, define MeQ-Small, and adopt consistent naming throughout.
4. Clarify the evaluation condition for large VLMs in Table 4.
5. Report fine-tuning hyperparameters (rank, lr, epochs, batch size, quantization settings).

MY FINAL SCORE: <score>3</score>
MY FINAL DECISION: <decision>Reject</decision>